secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-209160
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica Q2 net loss $6.3M, cash $19.1M; Auxora Phase 2b expands to India, AKI IND expected by year-end
--------------------------------------------------------------------------------

- Net loss $6.3M ($1.11/sh) in Q2 2023; cash $19.1M expected to fund operations for at least 12 months.
- CARPO Phase 2b trial of Auxora in acute pancreatitis with SIRS expanded to India; enrollment complete expected Q1 2024, topline data H1 2024.
- IND filing for Auxora in acute kidney injury expected by year-end 2023; trials could begin H1 2024 pending additional funding.
- Appointed Raven Jaeger as Chief Regulatory Officer and Andrew Cunningham as SVP Clinical Development; stock relisted on Nasdaq in June.
- Preclinical data in JCI Insight show Orai1 inhibition prevents progression of recurrent acute pancreatitis and early chronic pancreatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/d477357d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer